Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Supplement Health Claim Actions Draw Congressional Criticism

This article was originally published in The Tan Sheet

Executive Summary

FDA's recent actions regarding dietary supplement health claims are "cause for concern" and "sacrifice First Amendment rights for administrative convenience," Rep. Peter DeFazio (D-Ore.) states in a Jan. 12 letter to Commissioner Jane Henney, MD.

You may also be interested in...



Supplement Health Claim Regs Public Meeting Slated For Early 2000

FDA plans to hold a public meeting in the first quarter of 2000 to discuss possible ways to amend its general health claims regulations for dietary supplements, the agency announced in a Dec. 1 Federal Register notice.

Health Claims Petitions Cite Favorable Risk/Benefit Ratio - GU Prof

Pending health claims petitions for dietary supplements containing vitamin E, saw palmetto, pysllium, and folic acid/vitamins B6 and B12 are based on "such a favorable risk/benefits ratio that the public should be given proper information concerning the potential benefits of these nutraceuticals," Harry Preuss, MD, Georgetown University Medical Center, maintained at a May 25 press conference on Capitol Hill.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

UsernamePublicRestriction

Register

LL1132098

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel